Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
Alterations of endothelial function, inflammatory activation, and nitric oxide-cyclic guanosine monophosphate (NO-cGMP) pathway are involved in the pathophysiology of heart failure. Metabolic alterations have been studied in the myocardium of heart failure (HF) patients; alterations in ketone body and amino acid/protein metabolism have been described in patients affected by HF, as well as mitochondrial dysfunction and other modified metabolic signaling. However, their possible contributions toward cardiac function impairment in HF patients are not completely known. Recently, sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have emerged as a new class of drugs designed to treat patients with type 2 diabetes (T2D), but have also been shown to be protective against HF-related events and CV mortality. To date, the protective cardiovascular effects of these drugs in patients with and without T2D are not completely understood and several mechanisms have been proposed. In this review, we discuss on vascular and metabolic effects of SGLT2i and GLP-1 in HF patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Heart failure reviews - 28(2023), 3 vom: 11. Mai, Seite 733-744 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Correale, Michele [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
89750-14-1 |
|---|
| Anmerkungen: |
Date Completed 01.05.2023 Date Revised 02.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10741-021-10157-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329231359 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329231359 | ||
| 003 | DE-627 | ||
| 005 | 20231225204652.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10741-021-10157-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1097.xml |
| 035 | |a (DE-627)NLM329231359 | ||
| 035 | |a (NLM)34379224 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Correale, Michele |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.05.2023 | ||
| 500 | |a Date Revised 02.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a Alterations of endothelial function, inflammatory activation, and nitric oxide-cyclic guanosine monophosphate (NO-cGMP) pathway are involved in the pathophysiology of heart failure. Metabolic alterations have been studied in the myocardium of heart failure (HF) patients; alterations in ketone body and amino acid/protein metabolism have been described in patients affected by HF, as well as mitochondrial dysfunction and other modified metabolic signaling. However, their possible contributions toward cardiac function impairment in HF patients are not completely known. Recently, sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have emerged as a new class of drugs designed to treat patients with type 2 diabetes (T2D), but have also been shown to be protective against HF-related events and CV mortality. To date, the protective cardiovascular effects of these drugs in patients with and without T2D are not completely understood and several mechanisms have been proposed. In this review, we discuss on vascular and metabolic effects of SGLT2i and GLP-1 in HF patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Endothelial function | |
| 650 | 4 | |a GLP-1 RA | |
| 650 | 4 | |a Gliflozin | |
| 650 | 4 | |a Heart failure | |
| 650 | 4 | |a Metabolic effect | |
| 650 | 4 | |a SGLT2i | |
| 650 | 7 | |a Sodium-Glucose Transporter 2 Inhibitors |2 NLM | |
| 650 | 7 | |a Glucagon-Like Peptide 1 |2 NLM | |
| 650 | 7 | |a 89750-14-1 |2 NLM | |
| 700 | 1 | |a Lamacchia, Olga |e verfasserin |4 aut | |
| 700 | 1 | |a Ciccarelli, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Dattilo, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Tricarico, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Brunetti, Natale Daniele |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Heart failure reviews |d 1998 |g 28(2023), 3 vom: 11. Mai, Seite 733-744 |w (DE-627)NLM095528180 |x 1573-7322 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2023 |g number:3 |g day:11 |g month:05 |g pages:733-744 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10741-021-10157-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2023 |e 3 |b 11 |c 05 |h 733-744 | ||